Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3372689 in Early Symptomatic Alzheimer's Disease
NCT05063539Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of ceperognastat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Sep 2021; status: completed.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05063539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063539.